These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15758699)

  • 61. A risk-stratified approach to prostate-specific antigen screening.
    Keto CJ; Freedland SJ
    Eur Urol; 2011 Apr; 59(4):506-8. PubMed ID: 21292387
    [No Abstract]   [Full Text] [Related]  

  • 62. Screening for prostate cancer.
    Brawley OW; Ankerst DP; Thompson IM
    CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 64. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
    Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 67. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 68. Medical technologies for the diagnosis of prostate cancer.
    Fitzsimons NJ; Sun L; Moul JW
    Expert Rev Med Devices; 2007 Mar; 4(2):227-39. PubMed ID: 17359227
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 71. PSA: prostate-specific antigen, persisting scientific ambiguities.
    Harv Mens Health Watch; 2009 Jul; 13(12):1-6. PubMed ID: 19718841
    [No Abstract]   [Full Text] [Related]  

  • 72. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 73. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
    Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
    [No Abstract]   [Full Text] [Related]  

  • 76. Optimizing the diagnosis of prostate cancer in high-risk men: the supplementary biomarker approach.
    Kommu S; Persad R; Watkin N; Boyd PJ; Eeles R
    BJU Int; 2005 Jan; 95(1):5-7. PubMed ID: 15638884
    [No Abstract]   [Full Text] [Related]  

  • 77. A rational approach to prostate cancer.
    Kirk D
    Practitioner; 2000 Sep; 244(1614):750, 754-6, 758 passim. PubMed ID: 11048371
    [No Abstract]   [Full Text] [Related]  

  • 78. [Treatment strategy for prostate cancer].
    Kakehi Y
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():170-6. PubMed ID: 12599566
    [No Abstract]   [Full Text] [Related]  

  • 79. Serologic markers in prostate cancer.
    Harris D; Ruckle HC
    West J Med; 1996 Apr; 164(4):344-5. PubMed ID: 8732740
    [No Abstract]   [Full Text] [Related]  

  • 80. Detection and diagnosis of prostate cancer.
    Zaki S
    J S C Med Assoc; 2000 Feb; 96(2):53-6. PubMed ID: 10710899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.